Physician profile
Kameron Klosterman
NPI 1609984715
$3,211.86
in general payments reported to CMS, 2019-2025
26 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.30 · 2020: $153 · 2021: $662 · 2022: $704 · 2023: $566 · 2024: $483 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.35 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.31 | 2021-2025 | |
| Astellas Pharma US INC | $414.37 | 2022-2025 | Veozah |
| Dexcom, INC. | $302.48 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $249.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $222.46 | 2020-2022 | |
| Amgen INC. | $220.81 | 2020-2025 | Evenity, Prolia |
| Novo Nordisk INC | $197.16 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $158.98 | 2021-2022 | |
| Pfizer INC. | $123.20 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $94.04 | 2021 | |
| Exact Sciences Corporation | $89.34 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $86.34 | 2021-2024 | Breztri |
| Merck Sharp & Dohme LLC | $83.70 | 2020-2025 | Lagevrio, Vaqta, Gardasil |
| Sumitomo Pharma America, INC. | $82.52 | 2023-2024 | Gemtesa |
| Glaxosmithkline, LLC. | $65.09 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $55.33 | 2022-2023 | Proclaim |
| Novartis Pharmaceuticals Corporation | $38.20 | 2019-2023 | |
| Inari Medical, INC. | $33.14 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $26.68 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Inspire Medical Systems, INC. | $23.77 | 2024 | Inspire |
| Edwards Lifesciences Corporation | $22.66 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.21 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.00 | 2020 | |
| Almatica Pharma LLC | $17.22 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.21 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kameron Klosterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.